

State Pharmaceutical Assistance Programs Excluded from Medicaid Best Price*

State	Program Name
California (2)	Genetically Handicapped Persons Program California Children's Services
Connecticut (2)	Connecticut Pharmaceutical Assistance Contract to the Elderly and Disabled (ConnPACE) General Assistance Program
Delaware (4)	Non-Qualified Non Citizens Program Chronic Renal Disease Program Delaware Prescription Assistance Program Delaware Cancer Treatment Program
Illinois	Circuit Breaker
Maryland (2)	Maryland Pharmacy Assistance Program Maryland Kidney Disease Program
Minnesota (2)	Minnesota Prescription Drug Program General Assistance Medical Care Program
Missouri	Missouri Prescription Drug Plan
Montana	Mental Health Services Plan
Nevada (2)	Disability Rx Program Senior Rx Program
New Jersey (4)	Pharmaceutical Assistance to the Aged and Disabled (PAAD) Senior Gold Prescription Program Work First New Jersey General Assistance Program (WFNJ/GA) Medicare Part D Wraparound Program
New York	Elderly Pharmaceutical Insurance Coverage (EPIC)
North Carolina	Senior Care Program
Pennsylvania	Pharmaceutical Assistance Contract for the Elderly (PACE)
Rhode Island	Rhode Island Prescription Assistance for the Elderly (RIPAE)
Texas	Kidney Health Care Program
Vermont	VScript Expanded Program
Wisconsin (4)	SeniorCare (Above 200% FPL) Chronic Renal and Cystic Fibrosis Program Chronic Disease Program Home Hemophilia Program
TOTAL: 17 States	31 Programs

* The Medicaid statute allows manufacturers participating in the Medicaid Drug Rebate Program to exclude prices to State pharmaceutical assistance programs (SPAPs) from their Medicaid Best Price calculations. CMS has compiled a list of programs that meet the criteria to be considered SPAPs. Please note that this list only includes states that submitted a description of their programs to CMS for review based on the established criteria in CMS' Manufacturer Release #68 (April 1, 2005). The qualification of State-only programs as SPAPs is based on the information provided by the State and may be subject to further review if changes occur within the program.